CXCR4 and susceptibility to pneumonia measurement: Supporting this hypothesis, our data indicate that treatment with a CXCR4 antagonist, which normalized the accumulation of mature neutrophils in BM, promoting their release into peripheral blood, alleviated pneumonia severity, lowered bacterial counts in the lungs, reduced mortality, and restored lung neutrophil levels.